Drug Profile


Alternative Names: Human IgE pentapeptide; Pentyde

Latest Information Update: 28 Jul 1994

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dura Pharmaceuticals
  • Developer Bausch & Lomb; Carlbiotech; Dura Pharmaceuticals; Tanabe Seiyaku
  • Class Antiallergics; Immunoglobulin isotypes; Peptide fragments; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic conjunctivitis; Allergic rhinitis; Asthma

Most Recent Events

  • 29 Jul 1993 Discontinued-Clinical for Allergic conjunctivitis in USA (Ophthalmic)
  • 29 Jul 1993 Discontinued-Clinical for Allergic rhinitis in USA (Intranasal)
  • 29 Jul 1993 Discontinued-I for Allergic rhinitis in Japan (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top